Get the Stockscreener App
280.07
0.02%
0.06
After Hours:
280.25
0.18
+0.06%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc Stock (AMGN) Latest News
Amgen Drug Delivers More Weight Loss Than Competitors - Newsweek
New Apprentice Program Draws Talent from Unexpected Sources - Amgen
Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You (NASDAQ:AMGN) - Seeking Alpha
Amgen stock holds Buy rating, TD Cowen highlights MariTide's competitive edge in obesity treatment - Investing.com
BNP Paribas Reduces Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Stock Slips After More Analyst Criticism On Weight-Loss Drug Data: Retail Eyes ‘Great Buying Opportunity’ - MSN
Healthcare of Ontario Pension Plan Trust Fund Buys 303,016 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen’s MariTide achieves up to 20% weight loss in Phase 2 trial - World Pharmaceutical Frontiers
Glenmede Trust Co. NA Sells 42,532 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study - Yahoo Finance
Fmr LLC Buys 181,703 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
The Manufacturers Life Insurance Company Lowers Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Why Amgen's Weight Loss Result Is a Win for Eli Lilly - sharewise
Fisher Asset Management LLC Acquires 17,974 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen: Checks All The Wrong Boxes (NASDAQ:AMGN) - Seeking Alpha
AMGN Stock: MariTide Faces Dropout Challenges - Value the Markets
Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Amgen’s Phase II MariTide Data Lack Clarity Market Hoped For - Citeline
Weight Loss With Amgen Drug in Line With Eli Lilly Med, But Dosing Could Be Differentiator - MedCity News
Given dosing advantage, Amgen drug may not need best-in-class weight loss - BioCentury
Amgen raises awareness of thyroid eye disease - KOIN.com
Amgen: MariTide Underwhelms, But There Are Ways To Win (NASDAQ:AMGN) - Seeking Alpha
S&P 500 rises slightly following Trump tariff plans; Amgen weighs on Dow: Live updates - CNBC
New Obesity Drug MariTide Helps Patients Lose Up to 20% of Weight, Early Data Shows - The New York Times
Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations - Investopedia
Amgen shares fall on anti-obesity drug; rivals Novo and Lilly gain - Yahoo Finance
Amgen Stock Dives After Weight-Loss Drug Data. Here’s What to Know. - Barron's
Amgen share price plummets despite Phase II weight loss success - Clinical Trials Arena
Amgen decline on MariTide data could be due to lack of more details - MSN
Amgen decline on MariTide data could be due to lack of more details (AMGN:NASDAQ) - Seeking Alpha
Top Stock Movers Now: Amgen, Best Buy, JM Smucker, and More - MSN
Amgen stock slips as obesity drug study disappoints Wall Street - Yahoo Finance
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark - BioPharma Dive
Amgen Falls as Weight-Loss Shot Results Disappoint Street - Yahoo Finance
Amgen Drug Cut Weight in Closely Watched Study - MSN
Amgen Inc (AMGN) Trading Down 11.91% on Nov 26 - GuruFocus.com
Amgen tumbles to year's low despite weightloss trial success - Proactive Investors USA
Amgen’s MariTide falls short of analyst expectations in obesity - The Pharma Letter
Amgen’s Obesity Drug Making Waves - Baystreet.ca
Amgen Obesity Drug Cut Weight in Closely Watched Study - The Wall Street Journal
Amgen's obesity drug cuts weight by up to 20%, trial data drags down shares - Reuters.com
Principal Street Partners LLC Has $6.15 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound - Yahoo! Voices
Amgen stock touches 52-week low at $260.55 amid market shifts By Investing.com - Investing.com South Africa
Amgen stock touches 52-week low at $260.55 amid market shifts - Investing.com Australia
Amgen, Boeing share losses lead Dow's 200-point fall - MarketWatch
Amgen plunges 11%, hits lowest level in a year - baha news
Stocks Open Mixed. Amgen Is Dragging on the Dow. - Yahoo! Voices
Amgen shows 20% weight loss in once-monthly injectable MariTide - Yahoo Finance
D.A. Davidson & CO. Has $70.16 Million Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test - Yahoo! Voices
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau - Yahoo Finance
Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know. - Yahoo! Voices
Dai ichi Life Insurance Company Ltd Sells 3,041 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen’s stock slides 7.8% premarket after weight-loss drug data lags analyst expectations - MSN
Amgen drug leads to substantial weight loss in study, but questions remain about competitiveness - STAT
MariTide shows promise in obesity treatment, Amgen reports - Investing.com
Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms - MarketWatch
Amgen stock slips on data for weight loss drug (AMGN:NASDAQ) - Seeking Alpha
MariTide shows promise in obesity treatment, Amgen reports By Investing.com - Investing.com UK
Amgen (AMGN) Shot Helps Patients Lose 20% of Weight in Yearlong Study - Bloomberg
AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY - PR Newswire
AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM - Quantisnow
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):